Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6624443 | 0.97 | DPP8 (0.34) | DPP8DPP9ELANEPLCG1HTR2A | |
| SCHEMBL6623539 | 0.93 | CACNA1C (0.30) | — | |
| SCHEMBL6893286 | 0.88 | PLCG1 (0.33) | DPP8DPP9ELANEPLCG1HTR2A | |
| SCHEMBL7731889 | 0.88 | ELANE (0.37) | ELANEPLCG1HTR2A | |
| SCHEMBL6889515 | 0.88 | PLCG1 (0.32) | DPP8DPP9ELANEPLCG1HTR2A | |
| SCHEMBL6624626 | 0.87 | KDM4E (0.34) | DPP8DPP9ELANEPLCG1TGM2 | |
| SCHEMBL7722340 | 0.86 | ELANE (0.41) | ELANEPLCG1HTR2A | |
| SCHEMBL6891530 | 0.85 | DPP8 (0.30) | DPP8DPP9ELANE | |
| SCHEMBL7722386 | 0.85 | L3MBTL1 (0.40) | ELANEPLCG1HTR2A | |
| SCHEMBL6771548 | 0.84 | ELANE (0.33) | ELANEPLCG1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825187-B2 | CARBAPENEM DERIVATIVES SUBSTITUTED AT THE 2-POSITION WITH A SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP; USE AGAINST ANTIBIOTIC RESISTANT STAPHYLOCOCCUS AUREUS AND PSEUDOMONAS AERUGINOSA, ENTEROCOCCI AND INFLUENZA VIRUS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
| EP-1251134-A1 | NOVEL CARBAPENEM DERIVATIVES OF QUATERNARY SALT TYPE | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | DHPS, HDHD5, RRP15 | DPP8 173/4885DPP9 312/4885ELANE 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.